Company profile: Ankyra Therapeutics
1.1 - Company Overview
Company description
- Provider of anchored immunotherapy for cancer treatments as a biotech company developing immunotherapy solutions.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Ankyra Therapeutics
Lassen Therapeutics
HQ: United States
Website
- Description: Provider of antibody biotherapeutics, developing monoclonal antibodies including LASN01, which targets the IL-11 receptor to treat fibro-inflammatory diseases such as thyroid eye disease and idiopathic pulmonary fibrosis, and LASN500, which targets IL-18 binding protein to elevate IL-18 at the tumor site for cancer treatment.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lassen Therapeutics company profile →
Immune Design
HQ: United States
Website
- Description: Provider of vaccines and therapeutics for the prevention and treatment of infectious diseases, leveraging breakthrough technology and dedicated research to better understand the immune system and develop next-generation immune-based solutions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Immune Design company profile →
Courier Therapeutics
HQ: United States
Website
- Description: Provider of biotechnology solutions, including a protein therapeutics platform aimed at making cancer immunotherapy safer and more efficacious, with potential in autoimmune and inflammatory diseases; AI-driven drug discovery offerings such as the Opal Computational Platform, Target Discovery, and Logica; and development of investigational therapies like OPL-0401 for diabetic retinopathy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Courier Therapeutics company profile →
Obsidian Therapeutics
HQ: United States
Website
- Description: Provider of next-generation cell and gene therapies to extend adoptive immunotherapy, offering the cytoDRiVE platform that controls protein function using drug-responsive domains and FDA-approved small molecules, and OBX-115, a TIL cell therapy engineered to produce membrane-bound IL15 to eliminate co-administered high-dose IL2 in advanced or metastatic melanoma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Obsidian Therapeutics company profile →
Xilio Therapeutics
HQ: United States
Website
- Description: Provider of tumor-activated immuno-oncology therapies, including XTX101, an Fc-enhanced anti-CTLA-4 monoclonal antibody; XTX301, an engineered IL-12; XTX202, a tumor-selective protein-engineered IL-2; and XTX501, a tumor-activated PD1/IL2 bispecific, designed to enhance anti-tumor activity, reprogram the tumor microenvironment, improve tolerability, minimize peripheral toxicities, and overcome IL-2 receptor-mediated clearance.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Xilio Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Ankyra Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Ankyra Therapeutics
2.2 - Growth funds investing in similar companies to Ankyra Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Ankyra Therapeutics
4.2 - Public trading comparable groups for Ankyra Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →